Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 9:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 9,285 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
Interventions
MLN8237 (Alisertib)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Intramuscular Uricase-PEG 20

NCT01038947
Conditions
Gout, Hyperuricemia
Interventions
Uricase-PEG 20
Biological
Lead sponsor
EnzymeRx
Industry
Eligibility
40 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Conditions
Psoriasis
Interventions
ARQ-154 Foam 0.3%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bryant, Arkansas • Miami Lakes, Florida • Meridian, Idaho + 2 more
Conditions
Healthy Female Participants
Interventions
Navlimetostat, [14C]Navlimetostat
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 1 Interventional Results available

Notch Inhibitor in Advanced Cancer

NCT01158404
Conditions
Advanced Cancer
Interventions
LY900009 - Dose Escalation Phase (Part A), LY900009 - Dose Confirmation Phase (Part B)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Conditions
Acute Myeloid Leukemia
Interventions
Alvocidib, Cytarabine, Daunorubicin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina
Conditions
Healthy Volunteers
Interventions
TPIP F2, TPIP F3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions
IGN523
Drug
Lead sponsor
Igenica Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, PD 0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Chicago, Illinois • Kansas City, Kansas • Westwood, Kansas + 9 more
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Melanoma
Interventions
DS-8273a, Nivolumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumor, Adult
Interventions
ADA-011, PD(L)-1 inhibitor
Drug
Lead sponsor
Adanate, Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Scottsdale, Arizona • Orlando, Florida • Durham, North Carolina + 2 more
Conditions
Genital Warts
Interventions
GS-9191 ointment, GS-9191, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
Belinostat, Carboplatin, Paclitaxel
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Huntsville, Alabama • Santa Monica, California • Boynton Beach, Florida + 1 more
Conditions
Hepatic Impairment, Moderate Hepatic Impairment
Interventions
Zanzalintinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Conditions
Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases, Heart Diseases
Interventions
AdVEGFXC1
Biological
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Stanford, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 11 more
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Conditions
Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
Interventions
Ezabenlimab, BI 754111, BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
rhIL-15, Obinutuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Onalespib Lactate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

NCT05496738
Conditions
Healthy
Interventions
PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose, Intravenous placebo, subcutaneous placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Garden Grove, California • Long Beach, California • Los Alamitos, California + 3 more
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas